| 发明名称 | Internalizing ErbB2 antibodies | ||
| 摘要 | This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided. | ||
| 申请公布号 | US9388244(B2) | 申请公布日期 | 2016.07.12 |
| 申请号 | US201514627773 | 申请日期 | 2015.02.20 |
| 申请人 | The Regents of the University of California | 发明人 | Marks James D. D.;Poul Marie Alix |
| 分类号 | A61K39/395;C07K16/18;C07K16/28;C07K16/30;C07K17/06;C07K17/08;A61K47/48;C07K16/32;C12N15/86;A61K31/704;A61K9/00;A61K38/00 | 主分类号 | A61K39/395 |
| 代理机构 | Quine Intellectual Property Law Group, P.C. | 代理人 | Quine Intellectual Property Law Group, P.C. |
| 主权项 | 1. A single-chain variable fragment (scFv) antibody, wherein the antibody comprises each of three light chain variable region CDRs and each of three heavy chain variable region CDRs of F5 antibody as encoded by ATCC plasmid deposit designation PTA-7843. | ||
| 地址 | Oakland CA US | ||